Abstract

Objective: To analyze the seizure characteristics of children with anti-NMDAR encephalitis.Methods: This was a retrospective analysis of 50 children with anti-NMDAR encephalitis between July 1, 2013, and July 1, 2019.Results: Fifty children with anti-NMDAR encephalitis were included in this study, of which 34 (68.0%) had seizures. During the follow-up, three patients with anti-NMDAR encephalitis secondary to herpes simplex virus encephalitis had persistent seizures. The average duration of seizures in the remaining patients was 14.6 days (range 1–47 days). Compared to patients without seizures, those with seizures were more likely to experience consciousness disturbances (p = 0.008) and epileptic form discharge on electroencephalograms (p = 0.002). The Glasgow coma scale scores (p = 0.014), and Rankin scale scores (p = 0.019) were also different. The cranial MRI findings of children were reviewed, and clinical characteristics were compared between children without cranial lesions and those with lesions in the limbic system and neocortex. Compared to children in the non-lesion group, children with lesions in the limbic system and neocortex had a higher incidence of status epilepticus. Further, children in the limbic system and neocortical lesions groups were more likely to be taking anti-seizure medications (ASMs) and receive second-line drugs.Conclusion: Long-term oral ASMs are not recommended for most children with anti-NMDAR encephalitis. Children with involvement of the limbic system and neocortex are prone to status epilepticus, and sequelae of epilepsy may remain when the neocortex is involved.

Highlights

  • Since the discovery of the anti-NMDAR antibody in 2007 [1], reports of anti-NMDAR encephalitis have gradually increased, and it is currently the most common cause of autoimmune encephalitis [2, 3]

  • There are no universal guidelines for the management of seizures in children with anti-NMDAR encephalitis

  • This study retrospectively analyzed the clinical features and efficacy of anti-seizure medication (ASM) in children with anti-NMDAR encephalitis and summarizes our experience to provide a basis for the personalized treatment of seizures in children with anti-NMDAR encephalitis

Read more

Summary

Introduction

Since the discovery of the anti-NMDAR antibody in 2007 [1], reports of anti-NMDAR encephalitis have gradually increased, and it is currently the most common cause of autoimmune encephalitis [2, 3]. Seizures are often the presenting symptom in children with autoimmune encephalitis, occurring in up to 72% of cases [4]. Data regarding the seizure characteristics of children with anti-NMDAR encephalitis, as Seizures in Anti-NMDAR Encephalitis well as anti-epileptic treatments and long-term follow-up results, are limited. There are no universal guidelines for the management of seizures in children with anti-NMDAR encephalitis. This study retrospectively analyzed the clinical features and efficacy of anti-seizure medication (ASM) in children with anti-NMDAR encephalitis and summarizes our experience to provide a basis for the personalized treatment of seizures in children with anti-NMDAR encephalitis

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.